208 related articles for article (PubMed ID: 23701393)
41. Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years.
Boschetti G; Nancey S; Daniel F; Pariente B; Lerebours E; Duclos B; Bourreille A; Cadiot G; Fumery M; Moreau J; Marteau P; Bouhnik Y; Louis E; Flourié B;
Inflamm Bowel Dis; 2016 Dec; 22(12):2924-2932. PubMed ID: 27846194
[TBL] [Abstract][Full Text] [Related]
42. Editorial: Infliximab induction therapy in pediatric Crohn's disease-A cost-effective strategy?
Chanchlani N; Russell RK
Aliment Pharmacol Ther; 2024 Jul; 60(1):93-94. PubMed ID: 38773786
[No Abstract] [Full Text] [Related]
43. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
44. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
[TBL] [Abstract][Full Text] [Related]
45. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
46. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
[TBL] [Abstract][Full Text] [Related]
47. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.
Bodger K; Kikuchi T; Hughes D
Aliment Pharmacol Ther; 2009 Aug; 30(3):265-74. PubMed ID: 19438428
[TBL] [Abstract][Full Text] [Related]
49. Management for severe Crohn's disease: a lifetime cost-utility analysis.
Jaisson-Hot I; Flourié B; Descos L; Colin C
Int J Technol Assess Health Care; 2004; 20(3):274-9. PubMed ID: 15446756
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
52. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
[TBL] [Abstract][Full Text] [Related]
53. Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients.
Olbjørn C; Nakstad B; Småstuen MC; Thiis-Evensen E; Vatn MH; Perminow G
Scand J Gastroenterol; 2014 Dec; 49(12):1425-31. PubMed ID: 25310799
[TBL] [Abstract][Full Text] [Related]
54. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
[TBL] [Abstract][Full Text] [Related]
55. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
56. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
57. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
58. Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFα Therapy.
van der Valk ME; Mangen MJ; Severs M; van der Have M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk C; Vermeijden JR; Siersema PD; Leenders M; Oldenburg B; ;
J Crohns Colitis; 2015 Nov; 9(11):1016-23. PubMed ID: 26254056
[TBL] [Abstract][Full Text] [Related]
59. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
60. Cost-utility of initial medical management for Crohn's disease perianal fistulae.
Arseneau KO; Cohn SM; Cominelli F; Connors AF
Gastroenterology; 2001 Jun; 120(7):1640-56. PubMed ID: 11375946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
